-+ 0.00%
-+ 0.00%
-+ 0.00%

Nektar says rezpegaldesleukin shows early biomarker response in Phase 2b REZOLVE-AD atopic dermatitis study

PUBT·09/30/2026 14:30:39
Listen to the news
Nektar says rezpegaldesleukin shows early biomarker response in Phase 2b REZOLVE-AD atopic dermatitis study
  • Nektar Therapeutics disclosed new biomarker results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin in moderate-to-severe atopic dermatitis.
  • Findings were presented in a late-breaking oral session at the EADV Congress 2026.
  • Data showed early biological activity consistent with the drug’s regulatory T-cell mechanism, with changes emerging within the first weeks of dosing.
  • Early molecular shifts tracked with later clinical improvement in treated patients, supporting rezpegaldesleukin’s positioning as a broader immune-modulating approach.
  • Results underpin the company’s plan to advance the program into Phase 3 development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609301030PR_NEWS_USPR_____SF59259) on September 30, 2026, and is solely responsible for the information contained therein.